<b>Gapping up <br/>In reaction to strong earnings/guidance</b>:<br/><br/>HA +5.1%, FBR +2.6%, ORIT +2.5%, SGRY +2.3%, (Surgery Partners CFO Teresa Sparks is stepping down to pursue other opportunities; co also reaffirmed guidance at the upper half of the range for 2017 revs and Adj. EBITDA ), REV +1.8%, (Fabian Garcia steps down as President and CEO ), PHM +0.9%<br/><b>M&A news:</b><br/><br/>CALD +10.9% (to be acquired by SAP for $36.00 per share)<br/><b>Other news:</b><br/><br/>IMMY +47.6% (Imprimis Pharmaceuticals now making available two glaucoma drugs on FDA's drug shortage list), CRBP +11.9% (Corbus Pharma reaches agreement w/ the FDA regarding the design of its next study of lenabasum in the treatment of cystic fibrosis ), PTI +8.8% (still checking), GNBC +6.4% (to join S&P SmallCap 600), EXTR +6.2% (to join S&P SmallCap 600), GERN +6% (continued strength), DFFN +4.3% (doses the first patient in the Phase 3 clinical trial with trans sodium crocetinate in patients with newly-diagnosed inoperable glioblastoma multiforme), AR +4.1% (to evaluate various potential measures to address the discount in trading value of Antero's stock relative to some of the premier U.S. large capitalization upstream independents ), SMRT +4.1% (assembles team to improve performance and explore strategic alternatives ), PMT +4% (to join S&P SmallCap 600)<br/><b>Analyst comments:</b><br/><br/>GSS +8.7% (initiated with a Outperform at National Bank Financial)<br/>JBLU +1.5% (upgraded to Overweight from Neutral at JP Morgan)<br/>UAL +1.4% (upgraded to Overweight from Underweight at JP Morgan)<br/><b>Gapping down<br/>In reaction to disappointing earnings/guidance:</b><br/><br/>GGG -10.9%, PII -7.3%, RMBS -6.7%, MET -6.3%, SMG -5.8%, HOG -5.3%, DHR -4.6%, JVA -4.1%, IDTI -3%, RGA -2.6%, SNHY -2.4%, (also commenced an underwritten public offering of 4 million shares of common stock), WERN -2.4%, AET -2.4%, SANM -2.3%, CVTI -1.8%, CNHI -1.8%, PFE -1.6%, EAT -1.6%, AOS -1.3%, PFG -0.7%<br/>M&A news:<br/><br/>MXIM -9.9% (Renesas (RNECF) spokesperson has denied reports that it is in talks to acquire MXIM)<br/>Select Health/Ins provider related names showing weakness after JPM, AMZN and BRK.B healthcare partnership news:<br/><br/>UNH -6.5%, CVS -5.7%, CI -5.3%, CNC -5.2%, ANTM -5.1%, MOH -4.1%<br/><b>Other news:<br/></b><br/>EARS -18.9% (entered into a securities purchase agreement with investors providing for the purchase and sale of 12,499,999 common shares at a price of $0.44 per share), UCTT -7.3% (commenced an underwritten public offering of approximately $100 mln of its common stock; intends to disclose in connection with the offering former shareholder dispute), VTGN -6.5% (Issues Letter to Stockholders as Company Prepares to Initiate AV-101 Phase 2 Study for Major Depressive Disorder ), PE -5.8% (Parsley Energy expects 4Q17 net production of 80-81 MBoe per day and 51-52 MBo per day), AMRN -5.7% (commences offering of ADS), SLNO -2.8% (files for 14,165,541 share common stock offering by stockholders including 6,024,425 warrant shares that may be purchased upon exercise of issued and outstanding warrants), ITUS -2.7% (after making notable pull back - down 30% on Monday), GPOR -2.2% (provides Q4 update; budgets 2018 CapEx of $770-835 mln and approves $100 mln stock repurchase program ), CBAY -1.7% (commences underwritten public offering of common stock), .<br/><b>Analyst comments:</b><br/><br/>GRUB -3% (downgraded to Underweight from Equal Weight at Barclays)<br/>SWN -1.7% (downgraded to Underperform from Mkt Perform at Raymond James)<br/>LUV -1.6% (downgraded to at )<br/>X -1.6% (initiated with a Sell at Vertical Group)<br/>HZN -1.5% (downgraded to Market Perform from Outperform at BMO Capital Markets)<br/>ALK -1.4% (downgraded to Underweight from Neutral at JP Morgan)<br/>CL -1.1% (downgraded to Underperform from Outperform at Exane BNP Paribas)<br/><br/>Briefing.com